{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:51:53Z","timestamp":1782996713180,"version":"3.54.5"},"reference-count":24,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,11,1]]},"abstract":"<jats:p>Objectives. Identifying the determinants of the clinical presentation of pertussis is important for the purposes of diagnosis, therapy, and control and for predicting the disease\u2019s clinical course and choosing an appropriate case definition for surveillance. Potential determinants include vaccination status, antibiotic treatment, age at diagnosis, and sex, although the available data are inconsistent. The objective of this study was to compare the clinical course of pertussis in unvaccinated and vaccinated children in a well-defined and strictly studied population and to identify determinants of the disease\u2019s clinical presentation.<\/jats:p>\n               <jats:p>Methods. The clinical presentation of pertussis was studied in children who participated in a randomized, controlled clinical trial of efficacy of acellular pertussis vaccine. The children belonged to the same birth cohort and were followed from infancy to 6 years of age in 3 distinct periods (stages 1, 2, and 3). Children had received 1 of 2 three-component acellular pertussis vaccines produced by 2 manufacturers (diphtheria-tetanus-acellular pertussis from, Chiron Biocine [DTaP CB]; DTaP from SmithKline Beecham [DTaP SB]) or a diphtheria-tetanus vaccine only (DT; Chiron Biocine). Pertussis was confirmed through culture or serology. For each pertussis episode, information was collected on age at onset, sex, type of vaccine received, antibiotic treatment, culture results, duration of cough, spasmodic cough, and other symptoms. The simultaneous effect of potential determinants of clinical presentation of pertussis on the duration of cough and spasmodic cough was studied through analysis of variance models.<\/jats:p>\n               <jats:p>Results. The analysis was conducted on 788 laboratory-confirmed cases of pertussis. The median duration of cough in DT recipients varied from 52 to 61 days across the 3 stages, whereas the median duration of cough in DTaP recipients varied from 29 to 39 days. The median duration of spasmodic cough varied from 20 to 45 days in DT recipients and from 14 to 29 days in DTaP recipients. The results of the analysis of variance models showed that vaccination against pertussis reduced the length of cough from 3 to 10 days and the length of spasmodic cough from 4 to 8 days. Culture-positive patients had a cough 11 to 22 days longer and a spasmodic cough 12 to 22 days longer than culture-negative patients. Children who received an antibiotic had a duration of cough 6 to 11 days longer and spasmodic cough 4 to 13 days longer than untreated patients. Girls had a duration of spasmodic cough 7 days longer than boys only after 3 years of age. Age was directly related to duration of cough, whereas it was inversely related to duration of spasmodic cough after 3 years of age.<\/jats:p>\n               <jats:p>Conclusions. Duration of cough can be greatly influenced by vaccination status. A positive culture for Bordetella pertussis is more frequently found in patients with long duration of cough, and antibiotic therapy may be a marker of severe disease. Gender may affect the clinical presentation of pertussis only after infancy. Pertussis in older children may be characterized by short duration of spasmodic cough. These results should be taken into account in the clinical evaluation of patients with suspected pertussis. Clinical case definitions for the purpose of surveillance based on the presence of 2 weeks of spasmodic cough may not be appropriate where pertussis vaccination uptake is high.<\/jats:p>","DOI":"10.1542\/peds.112.5.1069","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"1069-1075","source":"Crossref","is-referenced-by-count":53,"title":["Clinical Presentation of Pertussis in Unvaccinated and Vaccinated Children in the First Six Years of Life"],"prefix":"10.1542","volume":"112","author":[{"given":"Alberto E.","family":"Tozzi","sequence":"first","affiliation":[{"name":"Istituto Superiore di Sanita\u0300, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Rava\u0300","sequence":"additional","affiliation":[{"name":"Ospedale Pediatrico Bambino Gesu\u0300, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta L.","family":"Ciofi degli Atti","sequence":"additional","affiliation":[{"name":"Istituto Superiore di Sanita\u0300, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Salmaso","sequence":"additional","affiliation":[{"name":"Istituto Superiore di Sanita\u0300, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Progetto Pertosse Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,11,1]]},"reference":[{"key":"2021120820282369600_R1","doi-asserted-by":"crossref","unstructured":"Christie CD, Marx ML, Marchant CD, Reising SF. The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children. N Engl J Med.1994;331:16\u201321","DOI":"10.1056\/NEJM199407073310104"},{"key":"2021120820282369600_R2","doi-asserted-by":"crossref","unstructured":"de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis.2000;6:348\u2013357","DOI":"10.3201\/eid0604.000404"},{"key":"2021120820282369600_R3","doi-asserted-by":"crossref","unstructured":"Khetsuriani N, Bisgard K, Prevots DR, et al. Pertussis outbreak in an elementary school with high vaccination coverage. Pediatr Infect Dis J.2001;20:1108\u20131112","DOI":"10.1097\/00006454-200112000-00003"},{"key":"2021120820282369600_R4","doi-asserted-by":"crossref","unstructured":"Heininger U. Recent progress in clinical and basic pertussis research. Eur J Pediatr.2001;160:203\u2013213","DOI":"10.1007\/PL00008429"},{"key":"2021120820282369600_R5","doi-asserted-by":"crossref","unstructured":"Jenkinson D. Natural course of 500 consecutive cases of whooping cough: a general practice population study. BMJ.1995;310:299\u2013302","DOI":"10.1136\/bmj.310.6975.299"},{"key":"2021120820282369600_R6","unstructured":"Salmaso S, Moiraghi A, Barale A, et al. Case definitions. Dev Biol Stand.1997;89:135\u2013142"},{"key":"2021120820282369600_R7","doi-asserted-by":"crossref","unstructured":"Yaari E, Yafe Zimerman Y, Scwartz SB, et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest.1999;115:1254\u20131258","DOI":"10.1378\/chest.115.5.1254"},{"key":"2021120820282369600_R8","doi-asserted-by":"crossref","unstructured":"Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J.1995;14:870\u2013874","DOI":"10.1097\/00006454-199510000-00010"},{"key":"2021120820282369600_R9","unstructured":"World Health Organization. Recommended surveillance standards for pertussis. Available at: http:\/\/www.who.int\/vaccine-surveillance\/deseasedesc\/rss_pertus.htm"},{"key":"2021120820282369600_R10","doi-asserted-by":"crossref","unstructured":"Mertsola J, Ruuskanen O, Eerola E, Viljanen MK. Intrafamilial spread of pertussis. J Pediatr.1983;103:359\u2013363","DOI":"10.1016\/S0022-3476(83)80403-X"},{"key":"2021120820282369600_R11","doi-asserted-by":"crossref","unstructured":"Heininger U, Klich K, Stehr K, Cherry J. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics.1997;100(6). Available at: http:\/\/www.pediatrics.org\/cgi\/content\/full\/100\/6\/e10","DOI":"10.1542\/peds.100.6.e10"},{"key":"2021120820282369600_R12","doi-asserted-by":"crossref","unstructured":"Deeks S, De Serres G, Boulianne N, et al. Failure of physicians to consider the diagnosis of pertussis in children. Clin Infect Dis.1999;28:840\u2013846","DOI":"10.1086\/515203"},{"key":"2021120820282369600_R13","doi-asserted-by":"crossref","unstructured":"Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med.1996;334:341\u2013348","DOI":"10.1056\/NEJM199602083340601"},{"key":"2021120820282369600_R14","doi-asserted-by":"crossref","unstructured":"Salmaso S, Mastrantonio P, Wassilak S, et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine.1998;13:1270\u20131275","DOI":"10.1016\/S0264-410X(98)00040-1"},{"key":"2021120820282369600_R15","doi-asserted-by":"crossref","unstructured":"Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics.2001;108:1\u20137","DOI":"10.1542\/peds.108.5.e81"},{"key":"2021120820282369600_R16","unstructured":"Official Pertussis Notification Data, 1992\u20131998. Rome, Italy: Italian National Institute of Statistics (ISTAT); 2000"},{"key":"2021120820282369600_R17","doi-asserted-by":"crossref","unstructured":"Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis.2001;32:1691\u20131697","DOI":"10.1086\/320754"},{"key":"2021120820282369600_R18","doi-asserted-by":"crossref","unstructured":"Halperin SA, Bortolussi R, Langley JM, Miller B, Eastwood BJ. Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infection. Pediatrics.1997;100:65\u201371","DOI":"10.1542\/peds.100.1.65"},{"key":"2021120820282369600_R19","doi-asserted-by":"crossref","unstructured":"Kerr JR, Preston NW. Current pharmacotherapy of pertussis. Expert Opin Pharmacother.2001;2:1275\u20131282","DOI":"10.1517\/14656566.2.8.1275"},{"key":"2021120820282369600_R20","unstructured":"Andrews R, Herceg A, Roberts C. Pertussis notifications in Australia, 1991\u20131997. Commun Dis Intell.1997;21:145\u2013148"},{"key":"2021120820282369600_R21","doi-asserted-by":"crossref","unstructured":"Campins-Marti\u0300 M, Cheng HK, Forsyth K, et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine.2002;20:641\u2013646","DOI":"10.1016\/S0264-410X(01)00393-0"},{"key":"2021120820282369600_R22","doi-asserted-by":"crossref","unstructured":"Fine P, Clarckson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis.1987;9:866\u2013883","DOI":"10.1093\/clinids\/9.5.866"},{"key":"2021120820282369600_R23","doi-asserted-by":"crossref","unstructured":"Grimprel E, Njamkepo E, Be\u0301gue\u0301 P, Guiso N. Rapid diagnosis of pertussis in young infants: comparison of culture, PCR, and infant\u2019s and mother\u2019s serology. Clin Diagn Lab Immunol.1997;4:723\u2013726","DOI":"10.1128\/cdli.4.6.723-726.1997"},{"key":"2021120820282369600_R24","doi-asserted-by":"crossref","unstructured":"Sotomayor J, Weiner LB, McMillan JA. Inaccurate diagnosis in infants with pertussis. An eight-year experience. Am J Dis Child.1985;139:724\u2013727","DOI":"10.1001\/archpedi.1985.02140090086039"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/5\/1069\/1002849\/pe1103001069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/5\/1069\/1002849\/pe1103001069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:26:19Z","timestamp":1639009579000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/112\/5\/1069\/28750\/Clinical-Presentation-of-Pertussis-in-Unvaccinated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,1]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2003,11,1]]},"published-print":{"date-parts":[[2003,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.112.5.1069","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,1]]}}}